您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Pemirolast
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Pemirolast
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Pemirolast图片
CAS NO:69372-19-6
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
Pemirolast 是一种具有口服活性的抗过敏试剂。Pemirolast 能够减轻紫杉醇处理导致的生物过敏反应,可用于对支气管哮喘和结膜炎的研究。
生物活性

Pemirolast is an orally active antiallergic agent. Pemirolast attenuates paclitaxel hypersensitivity reactions, can be used for bronchial asthma and conjunctivitis research[1]-[5].

体外研究
(In Vitro)

Pemirolast (1 μM-1 mM) inhibits A23187-induced LTC4 and ECP release from the eosinophils in a dose-dependent manner[1].
Pemirolast (0.1 mM and 1 mM) also inhibits PAF-induced and FMLP-induced ECP release from the eosinophils[1].
Pemirolast prevents the activation of human eosinophils to inhibit granule protein LTQ and ECP release, so that alleviates controlling allergic diseases[1].
Pemirolast (100 nM-1 mM; 1-15 min) fails to significantly inhibit histamine release from human conjunctival mast cells[2].
Pemirolast (0.1 μg/mL-0.01 mg/mL) inhibits the activation of signal transduction phospholipases C and AZ in rat peritoneal mast cells, by inhibiting the degranulation reaction of antigen and compound 48/80, suppressing the formation of 1,2-diacylglycerol and phosphatidylic acid[3].

体内研究
(In Vivo)

Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats[4].
Pemirolast (0.1-1 mg/kg; i.v.) inhibits taxel-induced pulmonary vascular hyperpermeability, and reverses paclitaxel-induced arterial PaO2 decreasing at a dosage of 1 mg/kg, 30 minutes after paclitaxel injection (15 mg/kg; i.v.)[4].
Pemirolast (1 mg/kg; i.v.) reverses taxel-induced elevation of the concentrations of sensory neuropeptides (CGRP, substance P and neurokinin A), 30 minutes after paclitaxel injection (15 mg/kg; i.v.)[4].
Pemirolast (10 mg/kg/d; p.o.; 4-5 d) significantly reduces cisplatin-induced kaolin intake on days 3 and 4 and inhibits cisplatin-induced substance P release in the cerebrospinal fluid (CSF) in rats[5].

Animal Model:Male Wistar rats (6-week-old, 160-250 g)[5]
Dosage:10 mg/kg
Administration:Oral gavage; 5 days: 1 h or 30 min before and 24, 48, 72 and 96 h (five times in total) after administration of cisplatin (2-10 mg/kg; i.v.)
Result:Inhibited the cisplatin-induced increase in kaolin intake on days 3 and 4, without decreasing in normal feed intake.
Animal Model:Male Wistar rats (6-week-old, 160-250 g)[5]
Dosage:10 mg/kg
Administration:Oral gavage; 4 days: 30 min before and 24, 48, 72 and 96 h (four times in total) after administration of cisplatin (5 mg/kg; i.v.).
Result:Significantly reversed the cisplatin-induced increase of substance P levels to vehicle levels in the CSF.
Clinical Trial
分子量

228.21

Formula

C10H8N6O

CAS 号

69372-19-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

溶解性数据
In Vitro: 

DMSO : 100 mg/mL(438.19 mM;Need ultrasonic)

DMF :< 1 mg/mL (ultrasonic)(insoluble)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM4.3819 mL21.9096 mL43.8193 mL
5 mM0.8764 mL4.3819 mL8.7639 mL
10 mM0.4382 mL2.1910 mL4.3819 mL